The Biden administration is mulling an authorization of a second booster shot for Americans over the age of 65 “as a result of the spread of the Omicron subvariant, BA.2,” according to Politico.

“The government needs to begin negotiating new supply deals with Pfizer and Moderna at the beginning of April to ensure doses are delivered by the fall . . . a process that cannot begin until Congress passes more funding,” one official told Politico.

Moderna is also taking the opportunity to push its questionably needed and largely ineffective “low-dose” vaccines for children between the ages of 6 months and 6 years, reported the AP.

The pharmaceutical company issued a press release Wednesday announcing “positive interim data from the Phase 2/3 KidCOVE study of the Moderna COVID-19 vaccine (mRNA-1273) in children 6 months to under 2 years and 2 years to under 6 years of age.”

“We now have clinical data on the performance of our vaccine from infants six months of age through older adults,” Stéphane Bancel, Chief Executive Officer of Moderna, said.

“Given the need for a vaccine against COVID-19 in infants and young children,” Bancel said, “we are working with the U.S. FDA and regulators globally to submit these data as soon as possible.”

“The announcement is positive news for parents who have anxiously awaited protection for younger tots and been continuously disappointed by setbacks and confusion over which shots might work and when,” gushed the AP. “The nation’s 18 million children under 5 are the only age group not yet eligible for vaccination.”